Darbepoetin alfa and history of thromboembolic events.
Gianluigi
G
Ferretti
Alessandra
A
Felici
Francesco
F
Cognetti
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068256:Darbepoetin alfa; D004311:Double-Blind Method; D000068817:Epoetin Alfa; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D018570:Risk Assessment; D016019:Survival Analysis; D013923:Thromboembolism / Q000453:epidemiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa